Fixed-Dose Tavapadon for Early Parkinson Disease

JAMA Neurology 2026 Open access

Read full text
Authors: R. Pahwa, E. Moro, Alberto J. Espay, AH Evans, Marie Saint-Hilaire, Diego R. Torres-Russotto, Raymond Sanchez, Matthew Leoni, Sridhar Reddy Duvvuri, Cari Combs, Ih Chang, Stacey Tringali
+3 more Joey Boiser, Cindy Zadikoff, Angelo Antonini
DOI: 10.1001/jamaneurol.2026.0590
Cited by: 11
References: 21

Abstract

Importance: Tavapadon is an oral, once-daily, selective D1/D5 agonist that may improve Parkinson disease (PD) motor symptoms while minimizing adverse events (AEs) associated with D2/D3 receptor activation. Objective: To evaluate the efficacy, safety, and tolerability of tavapadon in adults with early PD. Design, Setting, and Participants: TEMPO-1 was a phase 3, double-blind, placebo-controlled randomized clinical trial conducted at 102 sites across 12 countries between December 2019 and June 2024. Adults with early PD (

Fields of Study & Subjects

Parkinson's Disease Mechanisms and Treatments Parkinson's Disease and Spinal Disorders Electroconvulsive Therapy Studies

Publication details

Journal / source
JAMA Neurology
Publisher
American Medical Association (AMA)
Volume
83
Issue
5
Pages
452–452
Publication date
20 March 2026
Language
EN